Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04899960
Other study ID # KA-20004
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 1, 2020
Est. completion date November 1, 2021

Study information

Verified date May 2021
Source Hacettepe University
Contact Nadir Yalçin, MSc
Phone +905356849300
Email nadir.yalcin@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Drug-related problems in newborn babies have been reported with a rate of 4-30%. It is estimated that the higher rates of these problems in hospitalized children under the age of two are related to the variety of drugs used and the differences in the age, weight and diagnosis of the patients. In this context, with the clinical parameters and demographic data obtained in the first 24 hours of the patients hospitalized in the neonatal intensive care unit, machine learning algorithms are used to predict the risks that may arise from possible drug-related problems (prescribing and administration errors, side effects and drug-drug interactions) that may occur during hospitalization. The algorithm, which will be created by modeling with a high number of big data pool, is planned to be transformed into a clinical decision support system software that can be used easily in clinical practice with online and mobile applications. By processing the data of the patients to be included in the model, it is aimed to prevent and manage drug-related problems before they occur, as well as to provide cost-effective medşcation treatment to patients hospitalized in the neonatal intensive care unit, together with a reduction in the risk of drug-related mortality and morbidity.


Recruitment information / eligibility

Status Recruiting
Enrollment 512
Est. completion date November 1, 2021
Est. primary completion date November 1, 2021
Accepts healthy volunteers No
Gender All
Age group N/A to 28 Days
Eligibility Inclusion Criteria: - Newborns aged 0-28 days, - Consent form taken by the parents to participate in the study, - Patients admitted to neonatal intensive care unit or surgical wards Exclusion Criteria: - Have a postnatal age greater than 28 days, - Patients who will not be given any medication, - Patients who took part in any drug research within the last 28 days

Study Design


Intervention

Drug:
Clinical Pharmacist Intervention
Prevention of drug-related problems by clinical pharmacist in neonatal intensive care unit.

Locations

Country Name City State
Turkey Nadir Yalçin Ankara TR

Sponsors (1)

Lead Sponsor Collaborator
Hacettepe University

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Score for Neonatal Acute Physiology and Perinatal Extension Score Score for Neonatal Acute Physiology and Perinatal Extension Score is predictor of mortality in neonates. Through study completion, an average of 1 year.
Primary Neonatal Therapeutic Intervention Scoring System It is a therapy-based severity of illness (morbidity) assessment index. Through study completion, an average of 1 year.
Primary Neonatal Early-Onset Sepsis Risk Score It is use first week of life for determined sepsis risk with gestational age, highest maternal antepartum temperature, duration of rupture of membranes, etc. Through study completion, an average of 1 year.
Primary Neonatal Nutrition Screening Tool It could be used on all infants in the neonatal intensive care on a weekly basis by nursing staff to identify those at high risk of poor growth and in need of additional nutrition support during their stay. Through study completion, an average of 1 year.
Secondary Neonatal Adverse Event Severity Scale It describes a consensus process that led to the development of standard severity criteria for neonatal adverse events. The use of this tool could improve the quality of drug and device safety evaluations and facilitate the conduct of neonatal clinical trials. Through study completion, an average of 1 year.
Secondary The Drug Interaction Probability Scale This scale uses a series of questions relating to the potential drug interaction to estimate a probability score. Through study completion, an average of 1 year.
Secondary Adverse Drug Reactions Algorithm for Infants The new algorithm developed using actual patient data is more valid and reliable than the Naranjo algorithm for identifying adverse drug reactions in the neonatal intensive care unit population. Through study completion, an average of 1 year.
Secondary National Aeronautics and Space Administration Task Load Index NASA Task Load Index (NASA-TLX) is a widely used, subjective, multidimensional assessment tool that rates perceived workload in order to assess a task, system, or team's effectiveness or other aspects of performance. Through study completion, an average of 1 year.
See also
  Status Clinical Trial Phase
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT05007041 - Simultaneous RZV and aIIV4 Vaccination Phase 4
Suspended NCT02559960 - Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
Completed NCT05266300 - Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
Completed NCT03112083 - Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure N/A
Completed NCT05028361 - Simultaneous mRNA COVID-19 and IIV4 Vaccination Study Phase 4
Completed NCT04284553 - Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults N/A
Recruiting NCT06120712 - A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002) Phase 1/Phase 2
Completed NCT04181775 - Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)
Completed NCT02906657 - Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly N/A
Completed NCT03640273 - Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients Phase 2
Completed NCT02162147 - How Safe Are Our Pediatric Emergency Departments? N/A
Completed NCT01897870 - The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge. N/A
Completed NCT03725046 - Impact of an Optimized Communication on the Readmission for Adverse Drug Event N/A
Recruiting NCT04635956 - Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Phase 2
Active, not recruiting NCT05538065 - NUDGE-EHR Replication Trial at Mass General Brigham N/A
Completed NCT03442010 - Adverse Drug Events at Emergency Department
Recruiting NCT04791150 - Rheumatologic Adverse Events and Cancer Immunotherapy N/A
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT03665402 - A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status N/A